Mounjaro Online UK

Mounjaro Weight Loss Injection (5 mg)

Dual‑Action Tirzepatide Therapy for Strong Appetite Control, Metabolic Reset & Early Fat‑Loss Acceleration

Mounjaro 5 mg is the second therapeutic step in the Tirzepatide titration schedule. After completing the 2.5 mg starter phase, patients transition to 5 mg to strengthen appetite suppression, improve metabolic regulation, and initiate more noticeable fat‑loss results.

Powered by Tirzepatide, the world’s first dual GIP + GLP‑1 receptor agonist, Mounjaro delivers superior metabolic effects compared to GLP‑1‑only therapies — supporting faster, more consistent, and medically supervised weight reduction.

Key Features

• Contains Tirzepatide, a dual GIP/GLP‑1 receptor agonist
• Strong appetite suppression and craving reduction
• Enhances satiety and portion control
• Improves insulin sensitivity and metabolic balance
• Supports early fat‑loss acceleration
• Once‑weekly, pre‑filled injection pen
• Step‑2 dose in the official Mounjaro titration protocol

How Mounjaro 5 mg Works

Mounjaro activates two metabolic pathways simultaneously:

GLP‑1 Pathway

• Reduces appetite
• Slows gastric emptying
• Enhances satiety

GIP Pathway

• Improves insulin response
• Enhances fat metabolism
• Supports stable energy balance

This dual mechanism delivers stronger weight‑loss outcomes than GLP‑1 therapy alone.

Indications

Mounjaro 5 mg is prescribed for:

• Adults with BMI ≥30
• Adults with BMI ≥27 plus a weight‑related condition
• Patients progressing from the 2.5 mg starter dose
• Individuals requiring stronger appetite control and metabolic support

Benefits

• Strong appetite suppression
• Reduced cravings and emotional eating
• Improved blood sugar regulation
• Noticeable early fat‑loss acceleration
• Convenient once‑weekly dosing
• Smooth transition to 7.5 mg and higher therapeutic doses

Dosage & Titration

5 mg is used after completing the 2.5 mg starter phase:

PhaseDoseStarter2.5 mg**Step 25 mg**Step 37.5 mgStep 410 mgStep 512.5 mgStep 615 mg (maximum)

This structured escalation ensures tolerability and optimal therapeutic effect.

Safety Information

Common side effects:

• Nausea
• Bloating
• Fatigue
• Mild gastrointestinal discomfort

Not suitable for:

• Pregnant or breastfeeding individuals
• Patients with personal/family history of medullary thyroid carcinoma
• Individuals with MEN2 syndrome

Mounjaro must be used under medical supervision.

Professional Use & Prescription Requirement

Mounjaro (Tirzepatide) is a prescription‑only medication and must be provided by a licensed healthcare professional